The study aimed to clinically and radiographically compare the outcomes of pulpotomy using Mineral Trioxide Aggregate (MTA) and Human Amniotic Membrane (HAM) in primary molar teeth at 1, 3, 6, and 12 months. It was a randomized clinical trial with two groups: one treated with MTA (group I) and the other with HAM (group II).
Results indicated that both MTA and HAM exhibited 100% clinical success, with no signs of external resorption, periapical bone destruction, or internal resorption observed in either group at all four time intervals. However, periodontal ligament widening was noted in 30% of the MTA group participants at 1-month and 12-month follow-ups. In contrast, the HAM group showed a significant reduction in periodontal ligament widening, decreasing from 22.2% at 1-month to 11.1% at the 12-month follow-up.
The study concluded that HAM demonstrated favorable clinical and radiographic outcomes, advocating for its use as an alternative to MTA for pulpotomy in primary teeth. HAM is highlighted for its ease of availability, cost-effectiveness, ease of handling, and its ability to favor tissue regeneration, addressing the need for newer, effective agents beyond MTA.
